Drug Safety

, Volume 24, Issue 2, pp 119–147 | Cite as

Safety of Antihistamines in Children

  • Andrew P. Ten Eick
  • Jeffrey L. Blumer
  • Michael D. ReedEmail author
Review Article


The histamine H1 receptor antagonists (antihistamines) are an important class of medications used for the relief of common symptoms associated with hyperhistaminic conditions occurring in children and adults. This group of drugs may be subdivided into 3 classes, or generations, based upon their propensity to induce sedation and cardiotoxicity.

The first generation (classical) antihistamines are highly effective in treating hyperhistaminic conditions. However, they frequently induce sedation and may adversely affect a child’s learning ability. First generation antihistamine—induced sedation has been described to occur in more than 50% of patients receiving therapeutic dosages. Serious adverse events are unusual following overdoses of first generation antihistamines although life-threatening adverse events have been described.

When the so-called ‘second generation’ antihistamines terfenadine and astemizole were introduced they were widely embraced and quickly used by clinicians of all specialities, including paediatricians, as nonsedating alternatives to the first generation compounds. These new agents were found to be equally or more effective than first generation antihistamines in relieving symptoms associated with hyperhistaminic conditions without the soporific effects of the first generation agents. Unfortunately, after approximately 10 years of widespread clinical use, disturbing reports of potentially life-threatening dysrhythmias, specifically torsades de pointes, were described. Both terfenadine and astemizole have been shown in vitro to inhibit several ion channels, and in particular the delayed outward rectifier potassium channel in the myocardium, predisposing the heart to dysrhythmias.

The potential life-threatening cardiotoxicities of the second generation antihistamines led to the search for noncardiotoxic and nonsedating agents. Loratadine, fexofenadine, mizolastine, ebastine, azelastine and cetirizine are the first of the new third generation antihistamines. These drugs have been shown to be efficacious with few adverse events including no clinically relevant cytochrome P450 mediated metabolic—based drug-drug interactions or QT interval prolongation/cardiac dysrhythmias.

Appropriate treatment of an antihistamine overdose depends upon which class of compound has been ingested. There is no specific antidote for antihistamine overdose and treatment is supportive particularly for ingestions of first generation compounds. Ingestion of excessive doses of terfenadine or astemizole requires immediate medical attention. Children who accidentally ingest excessive doses of a third generation compound may usually be adequately managed at home. However, patients ingesting large amounts (approximately >3 to 4 times the normal therapeutic daily dose) should receive medical attention. These patients should be monitored for 2 to 3 hours after the ingestion and patients ingesting cetirizine should be advised about the potential for sedation.

The availability of newer generation antihistamine compounds has clearly added to the clinical effectiveness and patient tolerance of a widely prescribed class of drugs. These advances have also been accompanied by improved safety profiles, particularly in the case of third generation antihistamine overdose.


Allergic Rhinitis Terfenadine Cetirizine Loratadine Fexofenadine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported in part by NICHD Paediatric Pharmacology Research Unit contract HD 31323-07 (Dr Blumer and Dr Reed).


  1. 1.
    Handley D, Magnetti A, Higgins A. Therapeutic advantages of third generation antihistamines. Exp Opin Invest Drugs 1998; 7: 1045–54CrossRefGoogle Scholar
  2. 2.
    Mechanisms of antihistamines [discussion]. Clin Exp Allergy 1999; 29 Suppl. 3: 37–8Google Scholar
  3. 3.
    Richards DM, Brogden RN, Heel RC, et al. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984; 28(1): 38–61PubMedCrossRefGoogle Scholar
  4. 4.
    McTavish D, Goa K, Ferrill M. Terfenadine: an updated review of its pharmacological properties and therapeutic efficacy. Drugs 1990; 39: 466–74Google Scholar
  5. 5.
    Sorkin EM, Heel RC. Terfenadine. Areview of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29(1): 34–56PubMedCrossRefGoogle Scholar
  6. 6.
    Simons F. Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Clin Exp Allergy 1999; 29Suppl. 3: 125–32PubMedCrossRefGoogle Scholar
  7. 7.
    Flower F, Araujo O, Nieves C. Antihistamines. Int J Dermatol 1986; 25: 224–31CrossRefGoogle Scholar
  8. 8.
    Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71(2): 121–6PubMedGoogle Scholar
  9. 9.
    Arrighi H, Maiser W, Redding G, et al. The impact of allergic rhinitis in Seattle school children [abstract]. J Allergy Clin Immunol 1995; 95: 192Google Scholar
  10. 10.
    Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996; 17(4): 185–9PubMedCrossRefGoogle Scholar
  11. 11.
    Simons FE, Reggin JD, Roberts JR, et al. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994; 124(6): 979–83PubMedCrossRefGoogle Scholar
  12. 12.
    McLoughlin JA, Nall M, Berla E. Effect of allergy medication on children’s reading comprehension. Allergy Proc 1990; 11(5): 225–8PubMedCrossRefGoogle Scholar
  13. 13.
    Simons F, Simons K. H1 Receptor antagonists: clinical pharmacology and use in allergic disease. Pediatr Clin North Am 1983; 30(5): 899–914PubMedGoogle Scholar
  14. 14.
    Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999; 36(5): 329–52PubMedCrossRefGoogle Scholar
  15. 15.
    Nolen TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther 1997; 19(1): 39–55; discussion 2-3PubMedCrossRefGoogle Scholar
  16. 16.
    Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other sideeffects. Clin Exp Allergy 1999; 29Suppl. 3: 133–42PubMedCrossRefGoogle Scholar
  17. 17.
    Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittel Forschung 1992; 42(9): 1119–21PubMedGoogle Scholar
  18. 18.
    Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992; 14(1): 17–21PubMedGoogle Scholar
  19. 19.
    Harvey RP, Comer C, Sanders B, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97(6): 1233–41PubMedCrossRefGoogle Scholar
  20. 20.
    Vanden Bussche G, Rombaut N, Schuermans V, et al. Clinical activity of astemizole. A review of world wide data. In: Astemizole: a new nonsedative, long-acting H1 antagonist. Oxford: Medical Education Service, 1984: 101Google Scholar
  21. 21.
    Diffley D, Tran V, Snyder S. Histamine H1 receptors lavelled invivo: antidepressant and antihistamine interactions. Eur J Pharmacol 1980; 64: 177–81PubMedCrossRefGoogle Scholar
  22. 22.
    Mochizuki T, Yamatodani A, Okakura K, et al. Circadian rhythm of histamine release from the hypothalamus of freely moving rats. Physiol Behav 1992; 51(2): 391–4PubMedCrossRefGoogle Scholar
  23. 23.
    Monti JM. Involvement of histamine in the control of the waking state. Life Sci 1993; 53(17): 1331–8PubMedCrossRefGoogle Scholar
  24. 24.
    Orr E, Quay WB. Hypothalamic 24-hour rhythms in histamine, histidine, decarboxylase and histamine-N-methyltransferase. Endocrinology 1975; 96(4): 941–5PubMedCrossRefGoogle Scholar
  25. 25.
    Leurs R, Blandina P, Tedford C, et al. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998; 19(5): 177–83PubMedCrossRefGoogle Scholar
  26. 26.
    Reiner PB, Kamondi A. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current. Neuroscience 1994; 59(3): 579–88PubMedCrossRefGoogle Scholar
  27. 27.
    Arrang JM, Garbarg M, Tsien R, et al. Autoinhibition of brain histamine release by a novel class (H3) of histamine receptor. Nature 1983; 302: 832–7PubMedCrossRefGoogle Scholar
  28. 28.
    Endou M, Levi R. Histamine in the heart. Eur J Clin Invest 1995; 25Suppl. 1: 5–11PubMedGoogle Scholar
  29. 29.
    Schlicker E, Werthwein S, Zentner J. Histamine H3 receptor-mediated inhibition of noradrenaline release in the human brain. Fundam Clin Pharmacol 1999; 13(1): 120–2PubMedCrossRefGoogle Scholar
  30. 30.
    Bristow L, Bennett G. Biphasic effects of intra-accumbens histamine administration on spontaneous motor activity in the rat; a role for central histamine receptors. Br J Pharmacol 1988; 95(4): 1292–304PubMedCrossRefGoogle Scholar
  31. 31.
    Garbarg M, Tuong MD, Gros C, et al. Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 1989; 164(1): 1–11PubMedCrossRefGoogle Scholar
  32. 32.
    McLeod RL, Aslanian R, del Prado M, et al. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea-pig. J Pharmacol Exp Ther 1998; 287(1): 43–50PubMedGoogle Scholar
  33. 33.
    Lin JS, Saka iK, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousalmechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990; 523(2): 325–30PubMedCrossRefGoogle Scholar
  34. 34.
    Carruthers S, Shoeman D, Hignite C, et al. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther 1978; 23: 375–82PubMedGoogle Scholar
  35. 35.
    Wong L, Hendeles L, Weinberger M. Pharmacologic prophylaxis of allergic rhinitis: relative efficacy of hydroxyzine and chlorpheniramine. J Allergy Clin Immunol 1981; 67(3): 223–8PubMedCrossRefGoogle Scholar
  36. 36.
    Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994; 94(4): 716–24PubMedCrossRefGoogle Scholar
  37. 37.
    Spaeth J, Klimek L, Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996; 51(12): 893–906PubMedGoogle Scholar
  38. 38.
    Roth T, Roehrs T, Koshorek G, et al. Sedative effects of antihistamines. J Allergy Clin Immunol 1987; 80(1): 94–8PubMedCrossRefGoogle Scholar
  39. 39.
    Simons FE, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996; 7(1): 22–7PubMedCrossRefGoogle Scholar
  40. 40.
    Marshall PS, Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 1993; 71(3): 251–8PubMedGoogle Scholar
  41. 41.
    Vuurman EF, van Veggel LM, Sanders RL, et al. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 76(3): 247–52PubMedCrossRefGoogle Scholar
  42. 42.
    Uden DL, Huska DR, Kellenberger TA, et al. Antihistamines: a study of pediatric usage and incidence of toxicity. Vet Hum Toxicol 1984; 26(6): 469–72PubMedGoogle Scholar
  43. 43.
    Hestand HE, Teske DW. Diphenhydramine hydrochloride intoxication. J Pediatr 1977; 90(6): 1017–8PubMedCrossRefGoogle Scholar
  44. 44.
    Wyngaard JB, Seevers MH. The toxic effects of antihistaminic drugs. JAMA 1951; 145(5): 277–82CrossRefGoogle Scholar
  45. 45.
    Koppel C, Ibe K, Tenczer J. Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985. J Toxicol Clin Toxicol 1987; 25(1-2): 53–70PubMedCrossRefGoogle Scholar
  46. 46.
    Clark RF, Vance MV. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med 1992; 21(3): 318–21PubMedCrossRefGoogle Scholar
  47. 47.
    Rinder CS, D’Amato SL, Rinder HM, et al. Survival in complicated diphenhydramine overdose. Crit Care Med 1988; 16(11): 1161–2PubMedCrossRefGoogle Scholar
  48. 48.
    Krenzelok EP, Anderson GM, Mirick M. Massive diphenhydramine overdose resulting in death. Ann Emerg Med 1982; 11(4): 212–3PubMedCrossRefGoogle Scholar
  49. 49.
    Winn RE, McDonnell KP. Fatality secondary to massive overdose of dimenhydrinate. Ann Emerg Med 1993; 22(9): 1481–4PubMedCrossRefGoogle Scholar
  50. 50.
    Simonser L. Top 200 drugs of 1992. Pharm Times 1993; 59: 29–44Google Scholar
  51. 51.
    Guill MF, Buckley RH, Rocha Jr W, et al. Multicenter, doubleblind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. J Allergy Clin Immunol 1986; 78(1 Pt 1): 4–9PubMedCrossRefGoogle Scholar
  52. 52.
    Moller C, Andlin-Sobocki P, Blychert LO. Pharmacokinetics of astemizole in children. Rhinol Suppl 1992; 13: 21–5PubMedGoogle Scholar
  53. 53.
    Mangalan S, Patel RB, Gandhi TP, et al. Detection and determination of free and plasma protein-bound astemizole by thin-layer chromatography: a useful technique for bioavailability studies. J Chromatogr 1991; 567(2): 498–503PubMedCrossRefGoogle Scholar
  54. 54.
    Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999; 57(1): 31–47PubMedCrossRefGoogle Scholar
  55. 55.
    McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989; 38(5): 778–800PubMedCrossRefGoogle Scholar
  56. 56.
    Watson WT, Simons KJ, Chen XY, et al. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84(4 Pt 1): 457–64PubMedCrossRefGoogle Scholar
  57. 57.
    Desager JP, Dab I, Horsmans Y, et al. A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther 1993; 53(4): 431–5PubMedCrossRefGoogle Scholar
  58. 58.
    Spicak V, Dab I, Hulhoven R, et al. Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin Pharmacol Ther 1997; 61(3): 325–30PubMedCrossRefGoogle Scholar
  59. 59.
    Horsmans Y, Desager JP, Hulhoven R, et al. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993; 33(10): 929–32PubMedGoogle Scholar
  60. 60.
    Campoli-Richards DM, Buckley MM, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990; 40(5): 762–81PubMedCrossRefGoogle Scholar
  61. 61.
    Yamaguchi T, Hashizume T, Matsuda M, et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel Forschung 1994; 44(1): 59–64PubMedGoogle Scholar
  62. 62.
    Roberts DJ, Llenas J. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea-pig. Arzneimittel Forschung 1996; 46(8): 832–3PubMedGoogle Scholar
  63. 63.
    Simons FE, Watson WT, Simons KJ. Pharmacokinetics and pharmacodynamics of ebastine in children. J Pediatr 1993; 122(4): 641–6PubMedCrossRefGoogle Scholar
  64. 64.
    Simons FE, Bergman JN, Watson WT, et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 98(6 Pt 1): 1062–4PubMedCrossRefGoogle Scholar
  65. 65.
    Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55(2): 269-74; discussion 275-6Google Scholar
  66. 66.
    Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48(4): 617–37PubMedCrossRefGoogle Scholar
  67. 67.
    Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995; 28(5): 419–32PubMedCrossRefGoogle Scholar
  68. 68.
    Vorperian VR, Zhou Z, Mohammad S, et al. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28(6): 1556–61PubMedCrossRefGoogle Scholar
  69. 69.
    Handley D, Hong Y, Bakale R, et al. Norastemizole. Drug Future 1998; 23: 966–9CrossRefGoogle Scholar
  70. 70.
    Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10(6): 477–97PubMedCrossRefGoogle Scholar
  71. 71.
    Barlow JL, Beitman RE, Tsai TH. Terfenadine, safety and tolerance in controlled clinical trials. Arzneimittel Forschung 1982; 32(9a): 1215–7PubMedGoogle Scholar
  72. 72.
    Klein GL, Littlejohn Tr, Lockhart EA, et al. Brompheniramine, terfenadine, and placebo in allergic rhinitis. Ann Allergy Asthma Immunol 1996; 77(5): 365–70PubMedCrossRefGoogle Scholar
  73. 73.
    Kemp JP, Falliers CJ, Fox RW, et al. A multicenter, open study of the non-sedating antihistamine, terfenadine (Seldane), in the maintenance therapy of seasonal allergic rhinitis. Ann Allergy 1988; 60(4): 349–54PubMedGoogle Scholar
  74. 74.
    Buckley CEd, Klemawesch SJ, Lucas SK. Treatment of allergic rhinitis with a new selective H1 antihistamine: terfenadine. N Engl Reg Allergy Proc 1985; 6(1): 63–70PubMedCrossRefGoogle Scholar
  75. 75.
    Kemp JP, Buckley CE, Gershwin ME, et al. Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985; 54(6): 502–9PubMedGoogle Scholar
  76. 76.
    Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 76(5): 448–54PubMedCrossRefGoogle Scholar
  77. 77.
    Lockey RF, Findley S, Mitchell DQ, et al. Effects of cetirizine versus terfenadine in seasonal allergic rhinitis. Ann Allergy 1993; 70(4): 311–5PubMedGoogle Scholar
  78. 78.
    Ten Eick AP, Nakamura H, Reed MD. Drug-drug interactions in pediatric psychopharmacology. Pediatr Clin North Amer 1998; 45(5): 1233–64CrossRefGoogle Scholar
  79. 79.
    Davies A, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions interfenadine overdose [letter]. BMJ 1989; 298: 325PubMedCrossRefGoogle Scholar
  80. 80.
    Monahan B, Ferguson C, Killeavy E, et al. Torsade de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90PubMedCrossRefGoogle Scholar
  81. 81.
    Pulmonary-Allergy Drugs Advisory Committee. Proceedings of the Pulmonary-Allergy Drugs Advisory Committee. Rockville (MD): Food and Drug Administration, Public Health Service, US Department of Health and Human Services, 1990Google Scholar
  82. 82.
    Marion Merrell Dow, Inc. Important drug warning [letter]. Cincinnati (OH): Marion Merrell Dow Inc. 1990 Aug 6Google Scholar
  83. 83.
    Woosley R, Darrow WR. Analysis of potential adverse drug reactions - a case of mistaken identity. Am J Cardiol 1994; 74(2): 208–9PubMedCrossRefGoogle Scholar
  84. 84.
    Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269(12): 1532–6PubMedCrossRefGoogle Scholar
  85. 85.
    Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electro-physiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76(1): 110–9PubMedCrossRefGoogle Scholar
  86. 86.
    Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91(8): 2220–5PubMedCrossRefGoogle Scholar
  87. 87.
    Follmer C, Colatsky T. Block of delay rectifier potassium current, Ik, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990; 82: 289–93PubMedCrossRefGoogle Scholar
  88. 88.
    Ducic I, Ko CM, Shuba Y, et al. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 1997; 30(1): 42–54PubMedCrossRefGoogle Scholar
  89. 89.
    Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94(4): 817–23PubMedCrossRefGoogle Scholar
  90. 90.
    Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269(12): 1513–8PubMedCrossRefGoogle Scholar
  91. 91.
    Moss AJ, Morganroth J. Cardiac effects of ebastine and other antihistamines in humans. Drug Saf 1999; 21 Suppl. 1: 69–80Google Scholar
  92. 92.
    Chen Y, Woosley R. Electrophysiologic actions of astemizole [abstract]. Clin Pharmacol Ther 1994: 146Google Scholar
  93. 93.
    Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233–52PubMedCrossRefGoogle Scholar
  94. 94.
    Carlison M, editor. New drug application pipeline. 17th ed. Chevychase (MD): SDC Report, Inc., 1998Google Scholar
  95. 95.
    Zhou Z, Vorperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10(6): 836–43PubMedCrossRefGoogle Scholar
  96. 96.
    Kothari SS, Sharma S, Wasir HS. Terfenadine overdose induced polymorphous ventricular tachycardia. Indian Pediatr 1995; 32(10): 1107–08PubMedGoogle Scholar
  97. 97.
    Bishop R, Gaudry P. Prolonged Q-T interval following astemizole overdose. Arch Emerg Med 1989; 6: 63–5PubMedGoogle Scholar
  98. 98.
    Clark A, Love H. Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol 1991; 33: 165–67PubMedCrossRefGoogle Scholar
  99. 99.
    Craft TM. Torsade de pointes after astemizole overdose. BMJ (Clin Res Ed) 1986; 292(6521): 660CrossRefGoogle Scholar
  100. 100.
    Hoppu K, Tikanoja T, Tapanainen P, et al. Accidental astemizole overdose in young children. Lancet 1991; 338: 538–40PubMedCrossRefGoogle Scholar
  101. 101.
    Tobin JR, Doyle TP, Ackerman AD, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737–40PubMedCrossRefGoogle Scholar
  102. 102.
    Wiley JF, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120(5): 799–802PubMedCrossRefGoogle Scholar
  103. 103.
    Hasan RA, Zureikat GY, Nolan BM. Torsade de Pointes associated with astemizole overdose treated with magnesium sulfate. Pediatr Emerg Care 1993; 9: 23–5PubMedCrossRefGoogle Scholar
  104. 104.
    Broadhurst P, Nathan AW. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion. Br Heart J 1993; 70: 469–70PubMedCrossRefGoogle Scholar
  105. 105.
    Rao KA, Adlakha A, Verma-Ansil B, et al. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc 1994; 69(6): 589–93PubMedGoogle Scholar
  106. 106.
    Ikeda S, Oka H, Matunaga K, et al. Astemizole-induced torsades de pointes in a patient with vasospastic angina. Jpn Circ J 1998; 62(3): 225–7PubMedCrossRefGoogle Scholar
  107. 107.
    Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997; 96(2): 144–6PubMedGoogle Scholar
  108. 108.
    June RA, Nasr I. Torsades de pointes with terfenadine ingestion. Am J Emerg Med 1997; 15(5): 542–3PubMedCrossRefGoogle Scholar
  109. 109.
    Hilbert J, Radwanski E, Weglein R, et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 1987; 27(9): 694–8PubMedGoogle Scholar
  110. 110.
    Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 1990; 30(4): 364–71PubMedGoogle Scholar
  111. 111.
    Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine. Int Arch Allergy Immunol 1995; 107(1-3): 420PubMedCrossRefGoogle Scholar
  112. 112.
    Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58(3): 269–78PubMedCrossRefGoogle Scholar
  113. 113.
    Siegel S, Ellis E, Kemp J, et al. Efficacy and safety of loratadine in the treatment of allergic rhinitis in children [abstract A-2]. Allergy 1988; 43Suppl. 7: 5Google Scholar
  114. 114.
    Lutsky BN, Schuller JL, Cerio R, et al. Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population. Arzneimittel Forschung 1993; 43(11): 1196–9PubMedGoogle Scholar
  115. 115.
    Lutsky BN, Klose P, Melon J, et al. A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis. Clin Ther 1993; 15(5): 855–65PubMedGoogle Scholar
  116. 116.
    Boner AL, Richelli C, Castellani C, et al. Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis. Allergy 1992; 47(2 Pt 1): 98–102PubMedCrossRefGoogle Scholar
  117. 117.
    Del Carpio J, Kabbash L, Turenne Y, et al. Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84(5 Pt 1): 741–6PubMedCrossRefGoogle Scholar
  118. 118.
    VanCauwenberge P. New data on the safety of loratadine. Drug Invest 1992; 4: 283–91CrossRefGoogle Scholar
  119. 119.
    Hey JA, del Prado M, Egan RW, et al. Loratadine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea-pigs. Comparative studies with terfenadine and sedating antihistamines. Int Arch Allergy Immunol 1995; 107(1-3): 418–9PubMedCrossRefGoogle Scholar
  120. 120.
    Sanguinetti N, Jiang C, Durran M, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995; 81: 1–20CrossRefGoogle Scholar
  121. 121.
    Lacerda AE, Roy ML, Lewis EW, et al. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart [published erratum appears in Mol Pharmacol 1997 Oct; 52 (4): 754]. Mol Pharmacol 1997; 52(2): 314–22PubMedGoogle Scholar
  122. 122.
    Delpon E, Valenzuela C, Gay P, et al. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35(2): 341–50PubMedCrossRefGoogle Scholar
  123. 123.
    Caballero R, Delpon E, Valenzuela C, et al. Effect of descarboethoxyloratadine, the majormetabolite of loratadine, on the human cardiac potassium channel Kv1.5. Br J Pharmacol 1997; 122(5): 796–8PubMedCrossRefGoogle Scholar
  124. 124.
    Loratadine product information. 2nd rev. Kenilworth (NJ): Schering, 1998Google Scholar
  125. 125.
    Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia. Am J Cardiol 1994; 74(2): 207PubMedCrossRefGoogle Scholar
  126. 126.
    Hashizume T, Mise M, Terauchi Y, et al. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998; 26(6): 566–71PubMedGoogle Scholar
  127. 127.
    Moss AJ, Chaikin P, Garcia JD, et al. A review of the cardiac systemic side effects of antihistamines: ebastine. Clin Exp Allergy 1999; 26(Suppl. 3): 200–5CrossRefGoogle Scholar
  128. 128.
    Imai T, Taketani M, Suzu T, et al. In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos 1999; 27(8): 942–6PubMedGoogle Scholar
  129. 129.
    Nakajima M, Nakamura S, Tokudome S, et al. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 1999; 27(12): 1381–91PubMedGoogle Scholar
  130. 130.
    Anonymous. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. J Allergy Clin Immunol 1996; 97 (6): 1218–24Google Scholar
  131. 131.
    Tinkelman DG, Bucholtz GA, Kemp JP, et al. Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. Am Rev Respir Dis 1990; 141(3): 569–74PubMedCrossRefGoogle Scholar
  132. 132.
    Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittel Forschung 1998; 48(2): 173–8PubMedGoogle Scholar
  133. 133.
    Gillen M, Pentikis H, Rhodes G, et al. Pharmacokinetic and cardiac safety studies of ebastine and loratadine administered with ketoconazole [abstract]. J Clin Pharmacol 1998; 38: 867Google Scholar
  134. 134.
    Gillen M, Pentikis H, Rhodes G, et al. Pharmacokinetic and pharmacodynamic interaction of ebastine and erythromycin [abstract]. J Clin Pharmacol 1998; 38: 878Google Scholar
  135. 135.
    Moss AJ, Morganroth J. Cardiac effects of ebastine and other antihistamines in humans. Drug Saf 1999; 21: 69–80PubMedCrossRefGoogle Scholar
  136. 136.
    Sale M, Lyness W, Perhach J, et al. Lack of effect of coadministration of erythromycin with azelastine on pharmacokinetic or ECG parameters. Ann Allergy Asthma Imunol 1996; 76: 91Google Scholar
  137. 137.
    Delauche-Cavallier MC, Chaufour S, Guerault E, et al. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. Clin Exp Allergy 1999; 29Suppl. 3: 206–11PubMedCrossRefGoogle Scholar
  138. 138.
    Wiseman LR, Faulds D. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51(2): 260–77PubMedCrossRefGoogle Scholar
  139. 139.
    Riethmuller-Winzen H, Peter G, Buker KM, et al. Tolerability, pharmacokinetics and dose linearity of azelastine hydrochloride in healthy subjects. Arzneimittel Forschung 1994; 44(10): 1136–40PubMedGoogle Scholar
  140. 140.
    LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996; 76(2): 181–8PubMedCrossRefGoogle Scholar
  141. 141.
    Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittel Forschung 1996; 46(2): 153–8PubMedGoogle Scholar
  142. 142.
    Ohtani H, Sato H, Iga T, et al. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Biopharm Drug Dispos 1999; 20(2): 101–6PubMedCrossRefGoogle Scholar
  143. 143.
    Ko CM, Ducic I, Fan J, et al. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 1997; 281(1): 233–44PubMedGoogle Scholar
  144. 144.
    Hurst M, Spencer CM. Ebastine: an update of its use in allergic disorders. Drugs 2000; 59(4): 981–1006PubMedCrossRefGoogle Scholar
  145. 145.
    Data on file, Wallace Laboratories, Cranbury, 2000Google Scholar
  146. 146.
    Weiler JM, Donnelly A, Campbell BH, et al. Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1988; 82(5 Pt 1): 801–11PubMedCrossRefGoogle Scholar
  147. 147.
    Charpin D, Godard P, Garay RP, et al. Amulticenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995; 252(8): 455–8PubMedCrossRefGoogle Scholar
  148. 148.
    Gambardella R. Acomparison of the efficacy of azelastine nasal spray and loratidine tablets in the treatment of seasonal allergic rhinitis. J Int Med Res 1993; 21(5): 268–75PubMedGoogle Scholar
  149. 149.
    Morganroth J, Lyness WH, Perhach JL, et al. Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers. J Clin Pharmacol 1997; 37(11): 1065–72PubMedGoogle Scholar
  150. 150.
    Rosenzweig P, Patat A. Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies. Clin Exp Allergy 1999; 29Suppl. 3: 156–62PubMedCrossRefGoogle Scholar
  151. 151.
    Allegra product information. 2nd rev. New York (NY): Hoechst-Marion Roussel, 2000Google Scholar
  152. 152.
    Pagliara A, Testa B, Carrupt PA, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem 1998; 41(6): 853–63PubMedCrossRefGoogle Scholar
  153. 153.
    Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987; 59(6 Pt 2): 31–4PubMedGoogle Scholar
  154. 154.
    Pellegrin P, Jacqmin P, Van Bel P, et al. Mechanism of the renal clearance of cetirizine. Abstract 247. Euro J Drug Metab Pharmacokinet 1990; 15Suppl. 2: 31Google Scholar
  155. 155.
    Cetirizine (Zylert) product information. 2nd rev. New York (NY): Pfizer, 2000Google Scholar
  156. 156.
    Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54(1): 113–21PubMedGoogle Scholar
  157. 157.
    Carmeliet E. Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 1998; 124(4): 663–8PubMedCrossRefGoogle Scholar
  158. 158.
    Winder J, Noonan M, Lumry W, et al. Absence of QTc prolongation with cetirizine in children aged 6 to 11 years. Pediatr Asthma Allergy Immunol 1996; 10: 181–90CrossRefGoogle Scholar
  159. 159.
    Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clinical Pharmacol Ther 1994; 56: 295–301CrossRefGoogle Scholar
  160. 160.
    Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998; 64(6): 612–21PubMedCrossRefGoogle Scholar
  161. 161.
    Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997; 996 Pt 1: 860–1PubMedCrossRefGoogle Scholar
  162. 162.
    Hansen JJ, Feilberg Jorgensen NH. Accidental cetirizine poisoning in a four-year-old boy. Ugeskr Laeger 1998; 160(41): 5946–7PubMedGoogle Scholar
  163. 163.
    Giraud T. QT lengthening and arrhythmias associated with fexofenadine. Lancet 1999; 353(9169): 2072–3PubMedCrossRefGoogle Scholar
  164. 164.
    Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353: 980PubMedCrossRefGoogle Scholar
  165. 165.
    Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353; 2072–3CrossRefGoogle Scholar
  166. 166.
    Witek Jr TJ, Canestrari DA, Miller RD, et al. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol 1995; 74(5): 419–26PubMedGoogle Scholar
  167. 167.
    Tharion WJ, McMenemy DJ, Rauch TM. Antihistamine effects on the central nervous system, cognitive performance and subjective states. Neuropsychobiology 1994; 29(2): 97–104PubMedCrossRefGoogle Scholar
  168. 168.
    Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 1997; 157(20): 2350–6PubMedCrossRefGoogle Scholar
  169. 169.
    Seidel WF, Cohen S, Bliwise NG, et al. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987; 59(6 Pt 2): 58–62PubMedGoogle Scholar
  170. 170.
    Gengo FM, Gabos C. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987; 59(6 Pt 2): 53–7PubMedGoogle Scholar
  171. 171.
    Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Thera 1987; 42(3): 265–72CrossRefGoogle Scholar
  172. 172.
    Backhouse CI, Renton R, Fidler C, et al. Multicentre, double-blind comparison of terfenadine and cetirizine in patients with seasonal allergic rhinitis. Br J Clin Pract 1990; 44(3): 88–91PubMedGoogle Scholar
  173. 173.
    Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46(6): 1055–80PubMedCrossRefGoogle Scholar
  174. 174.
    Simons FE. H1-receptor antagonists. Comparative tolerability and safety. Drug Saf 1994; 10(5): 350–80PubMedCrossRefGoogle Scholar
  175. 175.
    Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157(5): 494–500PubMedCrossRefGoogle Scholar
  176. 176.
    Moskowitz H, Burns M. Effects of terfenadine, diphenhydramine, and placebo on skills performance. Cutis 1988; 42(4A): 14–8PubMedGoogle Scholar
  177. 177.
    Nicholson AN, Stone BM. Performance studies with the H1-histamine receptor antagonists, astemizole and terfenadine. Br J Clin Pharmacol 1982; 14: 199–202CrossRefGoogle Scholar
  178. 178.
    Vermeeren A, O’Hanlon JF. Fexofenadine’s effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998; 101(3): 306–11PubMedCrossRefGoogle Scholar
  179. 179.
    O’Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50(3): 234–42PubMedCrossRefGoogle Scholar
  180. 180.
    Napolitano C, Priori S, Schwartz P. Torsade de pointes: mechanisms and management. Drugs 1994; 47: 51–65PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Andrew P. Ten Eick
    • 1
    • 2
  • Jeffrey L. Blumer
    • 2
  • Michael D. Reed
    • 2
    Email author
  1. 1.Department of Pharmacy, College of PharmacyUniversity of OklahomaOklahoma CityUSA
  2. 2.Division of Paediatric Pharmacology and Critical Care, Rainbow Babies and Children’s Hospital and the Department of Paediatrics, School of MedicineCase Western Reserve UniversityClevelandUSA

Personalised recommendations